CRIS100
Druglocal application of CRIS100
NCT Number: NCT05739734
The goal of this clinical trial is to test CRIS100 treatment in participants with acute thoracic spinal cord injury. The main questions it aims to answer are:
* safety of CRIS100 * efficacy of CRIS100
Participants will receive 100 mcg CRIS100 in the epicenter of the spinal injury, within 72 hours of the trauma.
Trial opening soon.
Get Notified18 year–70 year
All sexes
Interventional
Early Phase 1
Participants with complete spinal cord injury between T2 and T10 (ASIA A, according to ISNCSCI, 2019 revision) and:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
local application of CRIS100
Time frame: 6 months
Possible, probable, or definitely CRIS 100-related SAE
Time frame: 6 months
Developing anti-CRIS100 antibodies
Time frame: 6 months
Liver enzyme values more than 2 times higher than the upper limit of normal.
Time frame: 6 months
Plasma urea and/or creatinine concentration above 2 times the upper limit of normality
Time frame: 6 months
Increase in WBC count greater than 20% of the upper limit of normal
Time frame: 6 months
Decrease in hemoglobin concentration greater than 20% of the lower limit of normal
Time frame: 6 months
Changes in spinal cord imaging (MRI or CT) that indicate worsening of the primary lesion
Time frame: 6 months
Improvement in AIS grade of one or more levels according to ISNCSCI.
Contact information is provided by the study sponsor or research team.
Jorge B Afiune, MD
CONTACT
Patricia C Bombarda, Post Graduate
CONTACT
Cristália Produtos Químicos Farmacêuticos Ltda.
Industry
Clinical Safety Study of the Application of CRIS100 in Participants With Acute Spinal Cord Injury
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01321333
Central Nervous System Diseases, Nervous System Diseases
Calgary, Alberta, Canada
View Trial Details